Status:
RECRUITING
Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
EURO BIO Scientific
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of pat...
Detailed Description
Methods : ICAME is a multicentric, blinded prospective randomized controlled trial. 710 patients originated from 10 centers will be included over a period of 12 months and follow-up for 24 months. All...
Eligibility Criteria
Inclusion criteria:
- 18 years or older
- Hospitalization for heart failure (NTproBNP(N-terminal pro-Brain Natriuretic Peptid) ≥450 pg/ml (ou BNP ≥400 pg/ml)
Exclusion criteria:
- Waiting for heart transplantation
- Scheduled valve surgery
- No fluent french
- Not able to provide informed consent
- Hemodynamic instability
- Poor outcome during the first week.
- Pregnancy
- Participating to other study
Key Trial Info
Start Date :
April 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
710 Patients enrolled
Trial Details
Trial ID
NCT04554277
Start Date
April 27 2021
End Date
January 1 2027
Last Update
September 30 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Lapeyronie Hospital
Montpellier, Occitanie, France, 34295
2
CHU Angers
Angers, France
3
CHU Besançon
Besançon, France
4
CH Béziers
Béziers, France